Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.89+0.45%BTC$85,520.00-0.35%ETH$2,697.04-0.63%GOLD$4,189.90+0.07%OIL$89.91+0.53%
Smart Investors Daily
SID Premium
OP

NASDAQ · OPK

OPKO Health, Inc.

Healthcare · Medical - Diagnostics & Research

$1.46

Down-$0.11 (-7.01%)

Updated Oct 7, 2026, 5:50 AM

SID Score

4.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.06B
P/E ratio
-7.64
Dividend yield
0.00%
52-week range
$0.98 – $1.75
Volume
2.46M
Avg. volume
2.42M

Price performance · OPK

OPK price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 6, 2026

OPK closed at $1.46 after 21 trading sessions, down 8.18% for the selected period.

Last close
$1.46
Period change
-8.18%
Period low
$1.46
Period high
$1.73
Daily close
View OHLC price history
OPK OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 6, 2026$1.59$1.59$1.46$1.462.46M
Oct 5, 2026$1.56$1.59$1.5401$1.571.65M
Oct 2, 2026$1.58$1.58$1.55$1.561.4M
Oct 1, 2026$1.61$1.61$1.55$1.572.5M
Sep 30, 2026$1.63$1.64$1.60$1.612.39M
Sep 29, 2026$1.62$1.635$1.61$1.621.73M
Sep 28, 2026$1.64$1.65$1.61$1.631.61M
Sep 25, 2026$1.65$1.66$1.62$1.641.53M
Sep 24, 2026$1.69$1.70$1.62$1.642.7M
Sep 23, 2026$1.71$1.74$1.68$1.701.78M
Sep 22, 2026$1.70$1.75$1.69$1.733.48M
Sep 21, 2026$1.67$1.69$1.64$1.691.78M
Sep 18, 2026$1.62$1.68$1.61$1.675.34M
Sep 17, 2026$1.64$1.65$1.61$1.621.71M
Sep 16, 2026$1.59$1.645$1.5821$1.612.29M
Sep 15, 2026$1.57$1.59$1.54$1.571.42M
Sep 14, 2026$1.59$1.60$1.54$1.562.15M
Sep 11, 2026$1.49$1.58$1.47$1.575.18M
Sep 10, 2026$1.53$1.53$1.48$1.491.45M
Sep 9, 2026$1.58$1.595$1.53$1.541.42M
Sep 8, 2026$1.625$1.625$1.5401$1.592.58M

Latest OPK news

The latest Smart Investors Daily articles mentioning OPK.

Stock researchCompany · Overview

OPK research

Overview

Company profile and research snapshot.

Company profile

OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$1.60
Implied upside
—
Analysts
—
OPK recent ratings
DateFirmRatingTarget
Apr 29, 2026Barrington ResearchMarket Perform—
Mar 2, 2026Barrington ResearchOutperform—
Nov 20, 2025JP MorganNeutral—
Oct 31, 2025JefferiesHold—
Oct 30, 2025Barrington ResearchOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 16, 2026

The Bull Case For OPKO Health (OPK) Could Change Following New Mazdutide Royalty-Backed Financing Strategy

Earlier this month, OPKO Health expanded its financing relationship with HealthCare Royalty by issuing US$125 million in senior secured notes backed by future mazdutide royalty payments from China, allowing it to raise capital without issuing new shares and with total repayments capped at 1.5 times the amount received. This royalty-backed financing structure highlights how OPKO Health is using its metabolic therapy partnerships to access non-dilutive funding while preserving potential...

Yahoo · Sep 14, 2026

OPKO Health (OPK) Cashes In A Future Royalty Stream Early

On August 13, OPKO Health (NASDAQ:OPK) expanded its financing relationship with HealthCare Royalty, a business of KKR, issuing an additional $125 million in senior secured notes secured by the royalty stream tied to mazdutide, the GLP-1 drug OPKO licensed to Eli Lilly and now collects royalties on in China. The notes mature in 2044, matching […]

Yahoo · Sep 11, 2026

OPKO Health Pivots to Therapeutics, Eyes Data-Rich 12 to 18 Months

OPKO Health (NASDAQ:OPK) outlined a strategy to shift its business mix toward therapeutics while continuing to streamline its diagnostics operations, with management highlighting a pipeline of early-stage clinical programs, external collaborations and capital available to fund development. Speaking

Yahoo · Sep 8, 2026

OPKO Health to Participate in the Wells Fargo 21st Annual Healthcare Conference

MIAMI, Sept. 08, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK), a fully-integrated healthcare company focused on delivering next-generation solutions for serious diseases across established global markets, today announced that Elias A. Zerhouni, M.D., President and Vice Chairman, and Adam Logal, Senior Vice President and Chief Financial Officer, will participate in the Wells Fargo 21st Annual Healthcare Conference at the Encore Boston Harbor, including a fireside chat on Thursday, Sep

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By